Category → The Working Scientist
My apologies to regular readers and my colleagues at C&EN for my month-long silence at the blog. I saw cobwebs on my laptop screen when I opened the back end this morning. Part of my hiatus came from complications of an infected molar extraction and my inability to concentrate. I’ve also been trying to take short Internet holidays over the last two months because all of the political nonsense in my state is negatively affecting my mental health.
But the tooth canyon is about 50% healed and our state legislature has finished, for now, shifting progressive North Carolina toward its pre-Research Triangle Park level of ignorance, racism, and poverty.
During this month, I came across an excellent post on the Scientific American
Yonath, a structural chemist recognized for her extensive work in showing how the ribosome catalyzes protein synthesis, has generally not made much of the fact that she’s only the fourth woman to receive the Nobel Prize in Chemistry, and the first since Dorothy Hodgkin in 1964.
As I did back in 2009 when interviewing Yonath at the North Carolina Biotechnology Center, Raven debates whether focusing on Yonath as a female scientist is a good thing for the cause of women scientists. Should we focus only on the accomplishments? Or should we focus on her accomplishments in the context of the distinct barriers often facing women scientists?
I’m equally torn, particularly since my 20-year laboratory career was advanced by a group that consistently ranged from 75% to 100% women. I never specifically recruited women to my laboratory but it seems that they might have self-selected for reasons not known to me. My activism in diversity in science extends back to my pharmacy faculty days at the University of Colorado where I assisted in selecting minority scholarship recipients for a generous program we had from the Skaggs Family Foundation.
The goings-on in North Carolina politics is not germane to this scientific discussion. We can speak all we want about our modern society being post-racial and having more women leaders than ever. But voter laws that disproportionately disenfranchise African-Americans and legislation that severely compromises women’s reproductive health tells me that we still need to pay attention to the influence of racial and gender attitudes.
Heck, even our Governor Pat McCrory showed his true colors yesterday while protestors, primarily women, were holding a vigil marking his signature of restrictive abortion legislation: He stepped out of the governor’s mansion to give protestors a plate of cookies and quickly returned behind the iron gates without any substantive engagement.
I’d be interested to hear from GlobCasino and C&EN readers after reading my own interview with Ada Yonath. Should we still be making an issue of advances in race, gender, and sexual orientation in chemistry?
I think yes, and it’s never been more important.
This post appeared originally on 14 December 2009 at the ScienceBlogs.com home of Terra Sigillata.
Last week in Stockholm (and Oslo), the 2009 Nobel Prize winners were gloriously hosted while giving their lectures and receiving their medals and diplomas. In Chemistry this year, the Nobel was shared by Venkatraman Ramakrishnan, Thomas A Steitz, and Ada E Yonath for their studies on the structure and function of the ribosome, a remarkable nucleoprotein complex that catalyzes the rapid, coordinated formation of peptide bonds as instructed by messenger RNA. My post on the day of the announcement in October was designed to counter the inevitable (and now realized) criticisms that the prize was not for “real” chemistry.
Only ten days later, we in the NC Research Triangle area were very fortunate to host Dr Yonath at the North Carolina Biotechnology Center for the Symposium on RNA Biology VIII, sponsored by The RNA Society of North Carolina.
Among the many noteworthy speakers was Dr Greg Hannon from Cold Spring Harbor Laboratory, a scientist who some feel was overlooked for the 2006 Nobel Prize in Medicine or Physiology, one where Andrew Fire and Craig Mello were recognized for RNA interference and gene silencing.
NC Biotech’s Senior Director of Corporate Communication, Robin Deacle, kindly invited me to an audience with Dr Yonath and two science reporters following Dr Yonath’s lecture. As you might suspect, I was quite honored to visit for awhile with the woman who defied the naysayers and successfully crystallized a bacterial ribosome, then used X-ray crystallography to determine its structure below three angstroms resolution. The fact that she also used natural product antibiotics to stabilize ribosomal structure added to my magnitude of admiration.
Continue reading →
As I alluded to earlier on this index page, I was fortunate to score the cover story the January 9th issue of the Research Triangle’s alternative weekly paper, INDY Week. Therein, I told the story of Robert J. Lefkowitz, MD, the biochemist and cardiologist who shared the Nobel Prize in Chemistry 2012 with his former cardiology fellow, Brian K. Kobilka, MD, of Stanford University.
In this first edition of pixels that didn’t make it to the final article, I want to follow on the moments after I took this photo after interviewing Bob for the article. He was kind enough to bring in his original Nobel medal and diploma for me to see and photograph (he’s currently having a replica made of the medal so that he doesn’t have to carry around the real one.).
I was fortunate to be able to tell the story of Duke University biochemist and cardiologist Dr. Robert J. Lefkowitz in the 9 January 2013 issue of the Research Triangle’s award-winning alt-weekly, INDY Week.
Even with editor Lisa Sorg graciously offering 3,000+ words for the story on one of the 2012 Nobel laureates in chemistry, some terrific bits of my interviews with Bob and major players in his story didn’t make it into the final version.
Over the next few days, I’ll post some of these gems. This page will index the running list of those posts.
The Nobel’s Great, But Take a Look at This! – Lefkowitz reveals where Duke men’s basketball sits in his list of priorities
As I wrote last Thursday, ACS Webinars featured an hour-long discussion on the perceived overabundance of PhD-level chemists and potential solutions to employment challenges. The site should have the entire discussion archived within a week.
I participated in the session and ended up posting my thoughts at the new Forbes.com home of my other blog, Take As Directed. I’m hoping to get comments from a wider group of readers over there who might have impact on hiring of chemistry PhDs.
One of the major points that struck me was the view by Harvard economist, Dr. Richard Freeman, that the chemistry job market might bounce back more quickly than the biosciences. But he views this comeback to occur slowly over the next three to four years.
Freeman attributes chemistry’s upper hand to two factors. First, US doctoral chemistry programs have had a fairly constant PhD supply rate over the last 40 years of approximately 2,000/year. In contrast, the biosciences have exploded from about 3,000 PhDs/year in the 1970s to 15,000 during 2010.
Second, Freeman states that chemistry is far less dependent on federal research funding since 50% to 75% of chemistry PhDs ultimately go on to work in industry. As such, he expects the recovering economy to help chemists far more than those in the biological and biomedical sciences.
I’d love to hear your feedback now or after the webinar is posted later this week. In the meantime, check out my thoughts over at Forbes.com.
Addendum: I’ve since learned that chemistry bloggers Chemjobber and See Arr Oh have posted a podcast discussing this ACS webinar.
Don’t say ACS have their heads in the sand. A webinar this afternoon will face head-on the reality of training to be a doctoral-level chemist in today’s job market.
Is higher education producing more doctoral scientists than the market can absorb? With the attendance rates at graduate schools increasing, has the private sector’s growth been able to keep up and will there be enough options for tomorrow’s PhDs? Join our two experts Richard Freeman and Paula Stephan as they share their viewpoints on the state of higher education, the economy and how industry and academia can better prepare current and future graduates.
I’m not privy to any other advance information than what’s on the ACS Webinars™ website but others I’ve viewed have been top-quality.
I obviously encourage viewing by current doctoral trainees in chemistry and postdocs. Giving yourself a competitive edge in this market is information anyone can use.
But I particularly urge undergrads currently interviewing for chemistry doctoral programs to tune in. One of the four primary discussion topics will be assessing graduate programs for their ultimate employment record of their trainees.
Take advantage of what your professional society is offering.
Doctoral Glut Dilemma: Are There Solutions?
Date: Thursday November 8, 2012 (TODAY!)
Time: 2:00-3:00 pm ET
To celebrate National Chemistry Week, the esteemed synthetic chemist blogger See Arr Oh put out a call for folks to describe to younger folks how they got where there are in the broad field of chemistry:
What do you do all day? What chemistry skills do you use in your line of work? How do you move up the ladder in chemistry? What do I need to do to be in your shoes?
The resulting answers from other bloggers — and any respondents, for that matter — will be compiled at his blog, Just Like Cooking, in what’s called a blog carnival. Specifically, contributors to blog carnivals are asked to respond to a theme or a series of questions. In this particular case, we are tagging our posts with the hashtag, #ChemCoach.
Here’s the list and below are my responses. You may find it helpful to play this Talking Heads video while reading my answers.
Your current job.
What you do in a standard “work day.”
What kind of schooling / training / experience helped you get there?
How does chemistry inform your work?
Finally, a unique, interesting, or funny anecdote about your career*
The most important question to ask yourself - If I were just coming into the field, would I learn something useful from your story?
How many of you could say this about your laboratory group?
In the hall outside the champagne reception for Bob Lefkowitz’s lab on Wednesday at Duke University Medical Center, I had a chance to catch up with Marti Delahunty, PhD. Delahunty is a research scientist in a connecting building but worked in the Lefkowitz group from 1998 until 2006.
This brief chat brings to mind Carmen Drahl’s post about one’s laboratory being your second family.
PIs, trainees, technicians, and administrators: Tell me if you’d be able to say the same about the environment of your laboratory.
As discussed in my previous post, I took a personal day off from work yesterday to bask in the excitement of a university community celebrating a Nobel prize for one of its most beloved researchers, Dr. Robert “Bob” Lefkowitz, MD. He joined Duke in 1973 when, he says, “it was not the powerhouse it is today.”
Lefkowitz will share the prize with his former trainee, Brian Kobilka, MD, now at Stanford University.
I had the honor of joining his laboratory’s champagne celebration in the morning and the Duke University press conference in the early afternoon. (The full 47-minute press conference streamed live and is archived here at Duke.).
I live barely three miles from Duke and had no idea when or if I’d ever have the chance to be so close to such an event. The Lefkowitz prize is particularly meaningful to me as he is a biochemist physician-scientist who also considers himself a pharmacologist. So, I write this not so much as a journalist but rather — as Duke Research Communications Director Karl Leif Bates put it — a fan boy.